15 results for author:"Furet P." in Literature citations
Results Customize
› Repeat search in UniProtKB (2)
| The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. Furet P., Chene P., De Pover A., Valat T.S., Lisztwan J.H., Kallen J., Masuya K. Bioorg. Med. Chem. Lett. 22:3498-3502(2012) · Mapped (1) |
| Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. Guagnano V., Furet P., Spanka C., Bordas V., Le Douget M., Stamm C., Brueggen J., Jensen M.R., Schnell C., Schmid H. et al. J. Med. Chem. 54:7066-7083(2011) · Mapped (1) |
| A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Tiedt R., Degenkolbe E., Furet P., Appleton B.A., Wagner S., Schoepfer J., Buck E., Ruddy D.A., Monahan J.E., Jones M.D. et al. Cancer Res. 71:5255-5264(2011) · Mapped (22) |
| Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Baffert F., Regnier C.H., De Pover A., Pissot-Soldermann C., Tavares G.A., Blasco F., Brueggen J., Chene P., Drueckes P., Erdmann D. et al. Mol. Cancer Ther. 9:1945-1955(2010) · Mapped (1) |
| New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck. Gommermann N., Buehlmayer P., von Matt A., Breitenstein W., Masuya K., Pirard B., Furet P., Cowan-Jacob S.W., Weckbecker G. Bioorg. Med. Chem. Lett. 20:3628-3631(2010) · Mapped (1) |
| Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. Jahnke W., Grotzfeld R.M., Pelle X., Strauss A., Fendrich G., Cowan-Jacob S.W., Cotesta S., Fabbro D., Furet P., Mestan J. et al. J. Am. Chem. Soc. 132:7043-7048(2010) · Mapped (1) |
| Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Pissot-Soldermann C., Gerspacher M., Furet P., Gaul C., Holzer P., McCarthy C., Radimerski T., Regnier C.H., Baffert F., Drueckes P. et al. Bioorg. Med. Chem. Lett. 20:2609-2613(2010) · Mapped (1) |
| Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Fabbro D., Manley P.W., Jahnke W., Liebetanz J., Szyttenholm A., Fendrich G., Strauss A., Zhang J., Gray N.S., Adrian F. et al. Biochim. Biophys. Acta 1804:454-462(2010) · Mapped (13) |
| Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. Kallen J., Goepfert A., Blechschmidt A., Izaac A., Geiser M., Tavares G., Ramage P., Furet P., Masuya K., Lisztwan J. J. Biol. Chem. 284:8812-8821(2009) · Mapped (41) |
| Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Cowan-Jacob S.W., Fendrich G., Floersheimer A., Furet P., Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D., Manley P.W. Acta Crystallogr. D 63:80-93(2007) · UniProtKB (1) · Mapped (1) |
| Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Sarno S., de Moliner E., Ruzzene M., Pagano M.A., Battistutta R., Bain J., Fabbro D., Schoepfer J., Elliott M., Furet P. et al. Biochem. J. 374:639-646(2003) · Mapped (1) |
| Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Furet P., Meyer T., Strauss A., Raccuglia S., Rondeau J.M. Bioorg. Med. Chem. Lett. 12:221-224(2002) · Mapped (1) |
| Structure-based design, synthesis, and X-ray crystallography of a high- affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic. Furet P., Garcia-Echeverria C., Gay B., Schoepfer J., Zeller M., Rahuel J. J. Med. Chem. 42:2358-2363(1999) · UniProtKB (1) |
| Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands. Rahuel J., Garcia-Echeverria C., Furet P., Strauss A., Caravatti G., Fretz H., Schoepfer J., Gay B. J. Mol. Biol. 279:1013-1022(1998) · UniProtKB (1) |
| Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Rahuel J., Gay B., Erdmann D., Strauss A., Garcia-Echeverria C., Furet P., Caravatti G., Fretz H., Schoepfer J., Grutter M.G. Nat. Struct. Biol. 3:586-589(1996) · Mapped (1) |